Pfizer · NSE: PFIZER · BSE: 500680
Q3 FY25 results · Oct–Dec 2024
Pfizer reported revenue from operations of ₹537.99 crore (down 0.4% from Q3 FY24) and net profit of ₹127.60 crore (down 1.8% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a standalone basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 537.99 | 539.97 | −0.4% | 588.59 | −8.6% |
| Other income | 42.76 | 35.85 | +19.3% | 43.07 | −0.7% |
| Total income | 580.75 | 575.82 | +0.9% | 631.66 | −8.1% |
| Profit before tax | 172.44 | 175.94 | −2.0% | 215.23 | −19.9% |
| Net profit for the period | 127.60 | 129.98 | −1.8% | 158.35 | −19.4% |
| EPS, basic (₹) | 27.89 | 27.12 | +2.8% | 34.61 | −19.4% |
| Net margin (%) | 23.7 | 24.1 | 26.9 |
Standalone
- Filed with BSE
- 31 Jan 2025, 17:34 IST
- Board meeting
- 31 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE